With an investment of over three million euros, Preomics successfully concludes its Series A financing round. The investors were BioM-Startup — alongside some business angels — again High-Tech Founders Fund (HTGF) and for the first time also win Think.Health Ventures.
Product development and the international expansion of sales — with the fresh capital, Preomics to start something very concrete. Garwin Pichler, Managing Director of the Munich startup, explains:
"Customers worldwide use our technologies, which enable standardized and efficient sample preparation for protein analysis and offer significant cost-benefit advantages. With the new capital, we plan to accelerate the expansion of global sales, with a focus on the US, and the development of new products."
Robust and reproducible results
Preomics develops and produces innovative technologies for the preanalytics of samples for mass spectrometry. Today, sample preparation for mass spectrometry is typically carried out according to in-house protocols. These processes are often slow, non-reproducible, not robust, and cannot be automated. These solutions are therefore very time-consuming and costly, which can even lead to the loss of valuable samples. The BioM startup Preomics addresses these problems with a standardized technology that enables robust and reproducible sample preparation results.
“We trust the management team”
Fabian Mohr, Investment Manager at HTGF, is pleased:
"We are very pleased to be investing in the Series A round to build on the success of the seed round. The company has made great progress, and we trust the management team to continue market expansion and product development."
For Michael Ruoff, Partner at Think.Health Ventures, said the key factors contributing to the investment were "the effective solution to a clear problem with positive market feedback combined with the expertise and ambition of the entire team." He says:
“We see great potential with Preomics to accelerate drug development for serious diseases, as Preomics products currently have an outstanding market position.”
